SUNRISE, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, ...
Transpire Bio, an integrated, clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced that the U.S. FDA has completed a ...
SUNRISE, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., a U.S. based, clinical-stage, revenue-generating biopharmaceutical company focused on developing inhaled therapeutics for ...
SUNRISE, Fla., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, ...
Trelegy Ellipta is a maintenance treatment for patients with asthma and COPD. "The FDA's acceptance of our ANDA filing for the substitutable generic version of high-strength Trelegy Ellipta is another ...
Transpire Bio announced today that its Chief Executive Officer, Dr. Xian-Ming Zeng, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2026 at ...
(MENAFN- GlobeNewsWire - Nasdaq) SUNRISE, Fla., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results